AstraZeneca PLC (STO:AZN)
1,704.00
+9.50 (0.56%)
At close: Dec 5, 2025
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B USD in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.83
Revenue / Employee
$616.41K
Employees
94,300
Market Cap
2.65T SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.67B |
| Elekta AB | 17.57B |
| Asker Healthcare Group AB | 16.41B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |
AstraZeneca News
- 1 day ago - Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Business Wire
- 2 days ago - FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN) - GuruFocus
- 2 days ago - AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval - GuruFocus
- 2 days ago - AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025 - GuruFocus
- 2 days ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Business Wire
- 2 days ago - AstraZeneca Shares Dip 0.7% Amid Patent Cliff Fears, But Pipeline Strength Fuels Long-Term Optimism - ABC Money
- 2 days ago - AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Benzinga
- 3 days ago - AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension - Nasdaq